Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 5/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1561048 | 0.89 | SLC6A2 (0.45) | TACR1SLC6A2BCHEPDPK1MTOR | |
| SCHEMBL1561047 | 0.89 | SLC6A2 (0.45) | TACR1SLC6A2BCHEPDPK1MTOR | |
| SCHEMBL13317630 | 0.89 | SLC6A2 (0.44) | TACR1SLC6A2BCHESLC5A2SLC5A1 | |
| SCHEMBL5981862 | 0.89 | SLC6A2 (0.44) | TACR1SLC6A2BCHESLC5A2SLC5A1 | |
| SCHEMBL28840559 | 0.89 | SLC6A2 (0.44) | TACR1SLC6A2BCHEPDPK1MTOR | |
| SCHEMBL3425832 | 0.89 | SLC6A2 (0.44) | TACR1SLC6A2BCHESLC5A2SLC5A1 | |
| SCHEMBL14356311 | 0.89 | SLC6A2 (0.44) | TACR1SLC6A2BCHESLC5A2SLC5A1 | |
| SCHEMBL7143032 | 0.89 | SLC6A2 (0.44) | TACR1SLC6A2BCHESLC5A2SLC5A1 | |
| SCHEMBL3954465 | 0.89 | SLC6A2 (0.44) | TACR1SLC6A2BCHESLC5A2SLC5A1 | |
| SCHEMBL3145889 | 0.89 | SLC6A2 (0.44) | TACR1SLC6A2BCHESLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044102-A1 | New Method for Preparing Isofagomine and Its Derivatives | AMICUS THERAPEUTICS INC (US) | 2017-02-16 | — | — | US | disclosed |
| US-9481700-B2 | Method for preparing isofagomine and its derivatives | AMICUS THERAPEUTICS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20140005372-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | AMICUS THERAPEUTICS INC (US) | 2014-01-02 | — | — | US | disclosed |
| US-8487110-B2 | Method for preparing isofagomine and its derivatives | AMICUS THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487110-B2 | Method for preparing isofagomine and its derivatives | AMICUS THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100160638-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | AMICUS THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160638-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | AMICUS THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| EP-2152265-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | Amicus Therapeutics, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090176830-A1 | TARTRATE SALT OF ISOFAGOMINE AND METHODS OF USE | AMICUS THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2008144773-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | AMICUS THERAPEUTICS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2007140212-A2 | TARTRATE SALT OF ISOFAGOMINE AND METHODS OF USE | AMICUS THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-1860101-A1 | Tartrate sale of isofagomine and methods of use | Amicus Therapeutics, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005372-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | ALDOA, FBP1, GALE | TACR1 4680/4885SLC6A2 75/4885BCHE 742/4885 |
| US-20100160638-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | ALDOA, FBP1, GALE | TACR1 4680/4885SLC6A2 75/4885BCHE 742/4885 |
| US-20090176830-A1 | TARTRATE SALT OF ISOFAGOMINE AND METHODS OF USE | GAA, GBA1, GALC | TACR1 1848/4885SLC6A2 36/4885BCHE 955/4885 |
| US-20170044102-A1 | New Method for Preparing Isofagomine and Its Derivatives | ALDOA, FBP1, GALE | TACR1 4680/4885SLC6A2 75/4885BCHE 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.